Healthcare ❯ Pharmaceuticals ❯ Drug Approval

FDA

Novo Nordisk Clinical Trials Bristol Myers Squibb Lenacapavir Regulatory Affairs Global Health Neffy Vaccine Oversight Wegovy Nereus Biologics License Application KYGEVVI Familial Chylomicronemia Syndrome Zepbound Monoclonal Antibodies New Drug Mechanisms Johnson & Johnson Esketamine SPRAVATO

Eli Lilly Jumps on GLP‑1 Momentum as 2026 Outlook Beats and Targets Rise

Wall Street credits GLP‑1 demand for the gains, noting pricing pressure.

FDA Issues Second Rejection of Atara’s EBV+ PTLD Therapy Tabelecleucel

FDA Approves Vanda’s Nereus, First New Motion Sickness Treatment in Over 40 Years

FDA Expands Addyi Use to Postmenopausal Women, Including Those Over 65

Arrowhead Gains FDA Approval for Redemplo as Results Surge and Shares Hit Three-Year High

WHO Endorses Twice-Yearly Lenacapavir Injections for HIV Prevention

FDA Approves Merck’s Enflonsia Monoclonal Antibody for Infant RSV Prevention